« Back
Home /
(8R,9S)-Talazoparib

(8R,9S)-Talazoparib

Item no.	HY-16106A-10mg
Manufacturer	MedChem Express
CASRN	1207456-00-5
Amount	10mg
Quantity options	100mg 10mM/1mL 10mg 1 mg 200mg 50mg 5 mg
Category	Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	98.36
Citations	[1]Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-
Smiles	O=C1NN=C2C3=C1C=C(F)C=C3N[C@@H](C4=CC=C(F)C=C4)[C@@H]2C5=NC=NN5C
ECLASS 5.1	30220300
ECLASS 6.1	30220300
ECLASS 8.0	32160605
ECLASS 9.0	32160605
ECLASS 10.0.1	32160490
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(8R,9S)-BMN-673; (8R,9S)-LT-673
Available
Product Description	(8R, 9S)-Talazoparib ((8R, 9S)-BMN-673) is an enantiomer of Talazoparib. (8R, 9S)-Talazoparib is an PARP1 inhibitor, with an IC50 of 144 nM[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	380.35
Clinical_Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : ≥ 50 mg/mL
Manufacturers Target	PARP
Isoform	PARP1
Pathway	Cell Cycle/DNA Damage; Epigenetics

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 10mg

available

Request delivery time